Saturday, October 31, 2026

Guardians of the Galaxy Vol. 3 breathes life into the MCU

Guardians of the Galaxy Vol. 3 breathes life into the MCU

Guardians of the Galaxy Vol. 3 is becoming the comeback that the MCU desperately needed.

After a string of box office duds, "Vol. 3" shows that some life is still left in the Comic Book Movie, and Superhero genres.

"Black Adam" and "Shazam: Fury of the Gods" were bonafide commercial and critical flops, while "Ant-Man and the Wasp: Quantumania" severely underperformed, and it might be the first Marvel Cinematic Universe project to lose money in theaters. Even "Black Panther: Wakanda Forever," the sequel to the 2018 box office juggernaut, ended up not breaking the one billion mark, settling on 860 million dollars compared to the 1,38 billion of the original.
"Guardians of the Galaxy" has always been a beloved, if off-beat, corner of the MCU, and it has always been referred to as a trilogy, but there were still many reasons to doubt this entry's success. Not only was there the aforementioned comic book and MCU fatigue, but superhero trilogy capers rarely stick the landing.

The last entry was also a whopping six years ago, a fact that might've been mitigated by regular appearances of the Guardians in the last two Avengers movies, a Thor movie, and a Disney+ Christmas Special. Lastly, there was the behind-the-scenes drama where writer and director James Gunn was temporarily fired due to the resurfacing of controversial old tweets, which could've influenced the audience's perspective.

All those worries turned out to be for naught, as "Vol. 3" has been critically acclaimed and is performing exceptionally well at the box office, reinforcing the fondness audiences have for this strange group of outcasts that include a humanoid alien tree and a grumpy cyborg raccoon.

In its opening weekend, "Vol.3" grossed $118 million domestically, an improvement over the first movie's $98 million but less than "Vol. 2" 's $147 million, while it made a series-best $168 million internationally. It is remarkable that it managed a paltry 48,9% drop in its second weekend, a rarity among blockbusters nowadays and the second smallest decline from an opening weekend in all of the MCU.

Much of this performance is attributed to solid word-of-mouth, even compared to its predecessors, and a rich emotional storyline centering on the raccoon character, his backstory, and his focus on animal rights through his perspective.

Despite all of this success, it's still unclear if there will be a fourth Guardians movie, as director James Gunn and stars Dave Bautista and Zoe Saldaña have already stated that they do not intend to return to these roles, or if it'll manage to overtake what is currently the year's box office champion "Super Mario Bros," which has amassed $1,210 billion so far.

Categories

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com